Bon Secours St. Mary's Hospital
Clinical research site in Richmond, Virginia · 5801 BREMO RD, RICHMOND, VA 23226-1907 · (804) 285-2011
As of September 2026, 30 paid clinical trials are recruiting at Bon Secours St. Mary's Hospital in Richmond, Virginia. Active studies at this site cover conditions such as Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 and Anatomic Stage IIIA Breast Cancer AJCC v8. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Recruiting clinical trials at Bon Secours St. Mary's Hospital (30)
Assessment of CCM in HF With Higher Ejection Fraction
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
E-Mindfulness Approaches for Living After Breast Cancer
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset
The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Vitamin D for Prostate Endocrine Therapy
Get new-trial alerts for Bon Secours St. Mary's Hospital
We'll email you whenever a new clinical trial starts recruiting at this research site in Richmond, VA. Unsubscribe anytime.
More research sites in Richmond
- Virginia Commonwealth University (159 trials)
- VCU Massey Comprehensive Cancer Center (106 trials)
- VCU Massey Cancer Center at Stony Point (51 trials)
- Virginia Cancer Institute (23 trials)
- Bon Secours Saint Mary's Hospital (23 trials)
- Bon Secours Cancer Institute at Reynolds Crossing (18 trials)
- Clinical Research Partners, LLC (13 trials)
- Bon Secours Richmond Community Hospital (12 trials)
- VCU Medical Center (9 trials)
- Virginia Commonwealth University Massey Cancer Center (9 trials)
Is this your research site?
This page is built from public ClinicalTrials.gov records. If you work here, we can correct it, send you the patients who apply, and build you a free website from your real studies — verify it with your work email, or read what we do for research sites.
Explore more
Paid clinical trials in Richmond, VA · Virginia clinical trials